Similar articles for PMID: 22159179

Year	Number of Results
1956	1
1959	1
1962	2
1964	1
1965	1
1978	1
1979	3
1980	2
1981	1
1984	3
1985	1
1986	1
1987	2
1988	2
1989	3
1990	3
1991	3
1992	2
1993	11
1994	11
1995	7
1996	10
1997	8
1998	9
1999	15
2000	9
2001	11
2002	14
2003	12
2004	8
2005	8
2006	4
2007	6
2008	5
2009	9
2010	12
2011	9
2012	18
2013	12
2014	13
2015	19
2016	25
2017	24
2018	13
2019	18
2020	17
2021	22
2022	17
2023	5
2024	0

1

Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.

Stillebroer AB, Zegers CM, Boerman OC, Oosterwijk E, Mulders PF, O'Donoghue JA, Visser EP, Oyen WJ. Stillebroer AB, et al. J Nucl Med. 2012 Jan;53(1):82-9. doi: 10.2967/jnumed.111.094896. Epub 2011 Dec 12. J Nucl Med. 2012. PMID: 22159179 Free article. Clinical Trial.

2

Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.

Stillebroer AB, Boerman OC, Desar IM, Boers-Sonderen MJ, van Herpen CM, Langenhuijsen JF, Smith-Jones PM, Oosterwijk E, Oyen WJ, Mulders PF. Stillebroer AB, et al. Eur Urol. 2013 Sep;64(3):478-85. doi: 10.1016/j.eururo.2012.08.024. Epub 2012 Aug 21. Eur Urol. 2013. PMID: 22980441 Clinical Trial.

3

Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer.

Divgi CR, O'Donoghue JA, Welt S, O'Neel J, Finn R, Motzer RJ, Jungbluth A, Hoffman E, Ritter G, Larson SM, Old LJ. Divgi CR, et al. J Nucl Med. 2004 Aug;45(8):1412-21. J Nucl Med. 2004. PMID: 15299069 Free article. Clinical Trial.

4

Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.

Brouwers AH, Mulders PF, de Mulder PH, van den Broek WJ, Buijs WC, Mala C, Joosten FB, Oosterwijk E, Boerman OC, Corstens FH, Oyen WJ. Brouwers AH, et al. J Clin Oncol. 2005 Sep 20;23(27):6540-8. doi: 10.1200/JCO.2005.07.732. J Clin Oncol. 2005. PMID: 16170161 Clinical Trial.

5

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA. Wiseman GA, et al. J Nucl Med. 2003 Mar;44(3):465-74. J Nucl Med. 2003. PMID: 12621016 Free article. Clinical Trial.

6

Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.

Breitz HB, Fisher DR, Goris ML, Knox S, Ratliff B, Murtha AD, Weiden PL. Breitz HB, et al. Cancer Biother Radiopharm. 1999 Oct;14(5):381-95. doi: 10.1089/cbr.1999.14.381. Cancer Biother Radiopharm. 1999. PMID: 10850323

7

Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.

Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC. Brouwers AH, et al. J Nucl Med. 2004 Feb;45(2):327-37. J Nucl Med. 2004. PMID: 14960657 Free article.

8

Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.

Blakkisrud J, Løndalen A, Dahle J, Turner S, Holte H, Kolstad A, Stokke C. Blakkisrud J, et al. J Nucl Med. 2017 Jan;58(1):55-61. doi: 10.2967/jnumed.116.180471. Epub 2016 Sep 1. J Nucl Med. 2017. PMID: 27587710 Free article.

9

Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.

Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ. Postema EJ, et al. J Nucl Med. 2003 Oct;44(10):1690-9. J Nucl Med. 2003. PMID: 14530488 Free article. Clinical Trial.

10

Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.

Siegel JA, Yeldell D, Goldenberg DM, Stabin MG, Sparks RB, Sharkey RM, Brenner A, Blumenthal RD. Siegel JA, et al. J Nucl Med. 2003 Jan;44(1):67-76. J Nucl Med. 2003. PMID: 12515878 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

382 results

Results by year